141335-10-6
| 中文名称 | 141335-10-6 |
|---|---|
| 中文同义词 | 化合物 T11825;化合物 LCB-2853 |
| 英文名称 | LCB-2853 |
| 英文同义词 | Benzeneacetic acid, 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl]methyl]-;LCB 2853,LCB2853 |
| CAS号 | 141335-10-6 |
| 分子式 | C21H24ClNO4S |
| 分子量 | 421.94 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 141335-10-6.mol |
| 结构式 |  |
141335-10-6 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 溶于二甲基亚砜 |
|
TXA 2 Receptor
|
In dog coronary stenosis, LCB 2853 shows a very high efficacy with ED 50 of 7.2 μg/kg. In rat venous thrombosis induced by combination of venous injury and blood stasis, perfused LCB 2853 decreases the weight of thrombi in a dose related manner with ED 50 of 220 μg/kg/min. In vivo, both against platelet aggregation and vasoconstriction, LCB 2853 shows an ED 50 lower than 1 mg/kg i.v. in rat AA-induced thrombocytopenia or U 46619-induced hypertension (ED 50 = 0.25 and 0.16 mg/kg) as well as in AA-induced sudden death in the mouse (ED 50 = 0.44 mg/kg). The U 46619-induced bronchoconstriction is blocked after i.v. administration of LCB 2853 (ED 50 = 18.4 μg/kg).